Please use this identifier to cite or link to this item:
Title: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue
Authors: Mostert, Bianca
Jiang, Yuqiu
Sieuwerts, Anieta M.
Wang, Haiying
Bolt-De Vries, Joan
Biermann, Katharina
Kraan, Jaco
Lalmahomed, Zarina
Van Galen, Anne
De Weerd, Vanja
Van Der Spoel, Petra
Ramírez-Moreno, Raquel 
Verhoef, Cornelis
Ijzermans, Jan N.M.
Wang, Yixin
Gratama, Jan Willem
Foekens, John A.
Sleijfer, Stefan
Martens, John W.M.
Keywords: Cetuximab Plus Irinotecan
Ras, et al
Issue Date: 2013
Publisher: 0020-7136
Journal: International Journal of Cancer 
Abstract: Although anti-EGFR therapy has established efficacy in metastatic colorectal cancer, only 10-20% of unselected patients respond. This is partly due to KRAS and BRAF mutations, which are currently assessed in the primary tumor. To improve patient selection, assessing mutation status in circulating tumor cells (CTCs), which possibly better represent metastases than the primary tumor, could be advantageous. We investigated the feasibility of KRAS and BRAF mutation detection in colorectal CTCs by comparing three sensitive methods and compared mutation status in matching primary tumor, liver metastasis and CTCs. CTCs were isolated from blood drawn from 49 patients before liver resection using CellSearch. DNA and RNA was isolated from primary tumors, metastases and CTCs. Mutations were assessed by co-amplification at lower denaturation temperature-PCR (Transgenomic), real-time PCR (EntroGen) and nested Allele-Specific Blocker (ASB-)PCR and confirmed by Sanger sequencing. In 43 of the 49 patients, tissue RNA and DNA was of sufficient quantity and quality. In these 43 patients, discordance between primary and metastatic tumor was 23% for KRAS and 7% for BRAF mutations. RNA and DNA from CTCs was available from 42 of the 43 patients, in which ASB-PCR was able to detect the most mutations. Inconclusive results in patients with low CTC counts limited the interpretation of discrepancies between tissue and CTCs. Determination of KRAS and BRAF mutations in CTCs is challenging but feasible. Of the tested methods, nested ASB-PCR, enabling detection of KRAS and BRAF mutations in patients with as little as two CTCs, seems to be superior.
ISSN: 0020-7136
DOI: 10.1002/ijc.27987
Source: International Journal of Cancer[ISSN 0020-7136],v. 133, p. 130-141
Appears in Collections:Artículos
Show full item record


checked on May 19, 2024


checked on Feb 25, 2024

Page view(s)

checked on Feb 24, 2024

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.